Skip to main content
. 2019 Jul 23;10(7):529. doi: 10.1038/s41419-019-1775-y

Fig. 4. RPPA analysis of pathways activated by NanoFEN in primary lung cancer spheroid cells (LCSCs).

Fig. 4

a Hierarchical clustering of RPPA results obtained on six LCSCs derived from different histotypes and one commercial lung cancer cell line (H292) treated with the respective dose of NanoFEN for 48 h: LCSC1 4.3 μM; LCSC2 3.8 μM and 1.9 μM; LCSC3 0.1μM and 50 nM; LCSC4 0.9 μM; LCSC5 4.2 μM; LCSC6 4.9 μM; H292 29 μM. The color-coded values (high = yellow, average = black, cyan = low) in the heatmap correspond to normalized intensities of averaged sample replicates (n = 3), standardized over the sample set analyzed (z score). A list of RPPA antibodies used here is reported in Supplementary Table 1. b Graphical representation of the activated (colored) and repressed (grey) pathways emerged from RPPA analysis in LCSCs treated as described in (a). Phosphorylation sites are outlined in green when they result in protein activation. c Table highlights the endpoints upregulated in control (white panel) and treated (yellow panel) lung cancer cells as described in (a)